Clinical Trial Update: Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C in renal transplant recipients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: King Abdulaziz Medical City | Conditions: Chronic Hepatitis C, Renal Transplant | Phase 4 | Status: COMPLETED